FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average bur	den							

0.5

hours per response:

	Check this box if no longer subject to							
$\neg$	Section 16. Form 4 or Form 5							
J	obligations may continue. See							
	Instruction 1(b).							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						. ,										
Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ ADMA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Guiheen Lawrence P.</u>				-	101,11	II DIO		<u>0100, 11</u>	<u>Ci</u> [ IIDivii	• 1	X	Director		10% O	wner	
(Last) (First) (Middle) C/O ADMA BIOLOGICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/22/2018							Officer (below)	give title	Other ( below)	specify	
465 STATE ROUTE 17					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc	6. Individual or Joint/Group Filing (Check Applicable				
(Street)					The state of the s						Line)	Line)				
RAMSE	Y N	J	07446								) Y		-	eporting Perso han One Repo		
(City)	(S	itate)	(Zip)													
		Ta	ble I - Non-I	Derivati	ve Se	curitie	s A	cquired, D	isposed of	, or Ben	eficially	Owned				
Date				Transacti ate Ionth/Day	Execution Date		Code (Instr. 5)		i (A) or :. 3, 4 and	5. Amoun Securities Beneficia Owned Fo	Form Ily (D) o ollowing (I) (In	Ownership orm: Direct 0) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)	
			Table II - De					•	sposed of, , convertib		-	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and of Securiti Underlying Derivative (Instr. 3 and			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownershij Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$4.91	06/22/2018		A		17,500		(1)	06/22/2028 <sup>(2)</sup>	Common Stock	17,500	\$0	17,500	D		

## **Explanation of Responses:**

- 1. The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.
- 2. The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

/s/ Lawrence P. Guiheen, by Brian Lenz as Attorney-in-fact

06/25/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.